Advertisement

Reply

      We appreciate the thoughtful comments of Koesters et al. (
      • Weinmann S.
      • Becker T.
      • Koesters M.
      Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: Meta-analysis.
      ). We were of course aware of their meta-analysis, which focused on a subset of the published studies comparing venlafaxine and various selective serotonin reuptake inhibitors (SSRIs) and regret that their report was not published in time to be available for discussion in our article. With respect to the first point raised by Koesters et al., we agree that the differences between the results of their meta-analysis and ours are small. We also agree that publication bias can distort the results of meta-analyses; this is why we included all randomized double blind trials comparing venlafaxine and SSRIs in major depressive disorder conducted by Wyeth before 2007, whether published or not. Although we do not believe that Koesters et al. intended to suggest that their strategy for study inclusion was superior to the one used in the COMPARE study (Comprehensive Analysis of Remission), we wish to clarify that all the studies included in the primary analyses of COMPARE were double-blind, randomized controlled trials and, as such, would qualify as “more rigorous studies” within most systems of scoring treatment outcome research.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Weinmann S.
        • Becker T.
        • Koesters M.
        Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: Meta-analysis.
        Psychopharmacology (Berl). 2008; 196: 511-520
        • Keller M.B.
        • Trivedi M.H.
        • Thase M.E.
        • Shelton R.C.
        • Kornstein S.G.
        • Nemeroff C.B.
        • et al.
        The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: Outcomes from the acute and continuation phases.
        Biol Psychiatry. 2007; 62: 1371-1379
        • Cipriani A.
        • Furukawa T.A.
        • Salanti G.
        • Geddes J.R.
        • Higgins J.P.
        • Churchill R.
        • et al.
        Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis.
        Lancet. 2009; 373: 746-758
        • Fossati R.
        • Confalonieri C.
        • Apolone G.
        • Cavuto S.
        • Garattini S.
        Does a drug do better when it is new?.
        Ann Oncol. 2002; 13: 470-473
        • Turner E.H.
        • Matthews A.M.
        • Linardatos E.
        • Tell R.A.
        • Rosenthal R.
        Selective publication of antidepressant trials and its influence on apparent efficacy.
        N Engl J Med. 2008; 358: 252-260
        • Zanardi R.
        • Franchini L.
        • Serretti A.
        • Perez J.
        • Smeraldi E.
        Venlafaxine versus fluvoxamine in the treatment of delusional depression: A pilot double-blind controlled study.
        J Clin Psychiatry. 2000; 61: 26-29
        • Oslin D.W.
        • Ten Have T.R.
        • Streim J.E.
        • Datto C.J.
        • Weintraub D.
        • DiFilippo S.
        • Katz I.R.
        Probing the safety of medications in the frail elderly: Evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents.
        J Clin Psychiatry. 2003; 64: 875-882

      Linked Article

      • Regarding “Comprehensive Analysis of Remission (COMPARE) with Venlafaxine Versus SSRIs”
        Biological PsychiatryVol. 66Issue 5
        • Preview
          Nemeroff et al. (1) present a comprehensive meta-analysis of venlafaxine versus selective serotonin reuptake inhibitor (SSRI) in the treatment of major depression and address the important question of whether there are differences in efficacy between newer antidepressants. The authors show a small but significant advantage of venlafaxine over fluoxetine in achieving remission. They report, compared with all SSRIs, a number needed to treat (NNT) of 17, which would be of public health relevance. In a recent review (2) based on published studies with more rigorous and restrictive inclusion criteria, we could not show a statistically significant advantage of venlafaxine versus SSRIs in remission rates but found only a small advantage in response rates.
        • Full-Text
        • PDF